$elv 2024 Q3 10-Q

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$45.11B	$43.89B	$43.67B
YoY Change	5.27%	0.49%	13.05%
Cost Of Revenue	$5.093B	$4.820B	$4.327B
YoY Change	9.57%	11.39%	40.99%
Gross Profit	$40.01B	$39.07B	$39.35B
YoY Change	4.74%	-0.71%	10.63%
Gross Profit Margin	88.71%	89.02%	90.09%
Selling, General & Admin	$5.269B	$5.066B	$4.818B
YoY Change	-3.67%	5.15%	12.86%
% of Gross Profit	13.17%	12.97%	12.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$231.0M	$0.00	$433.0M
YoY Change	-45.77%	-100.0%	10.18%
% of Gross Profit	0.58%	0.0%	1.1%
Operating Expenses	$5.269B	$5.066B	$40.97B
YoY Change	-3.67%	-87.63%	859.71%
Operating Profit	$1.408B	$2.765B	$2.628B
YoY Change	-19.82%	5.21%	11.03%
Interest Expense	$300.0M	$280.0M	-$261.0M
YoY Change	15.83%	-207.28%	-225.48%
% of Operating Profit	21.31%	10.13%	-9.93%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.373B	$2.986B	$2.441B
YoY Change	-16.99%	22.33%	13.91%
Income Tax	$365.0M	$685.0M	$585.0M
% Of Pretax Income	26.58%	22.94%	23.97%
Net Earnings	$1.016B	$2.300B	$1.853B
YoY Change	-21.18%	24.12%	12.1%
Net Earnings / Revenue	2.25%	5.24%	4.24%
Basic Earnings Per Share	$4.38	$9.91	$7.83
Diluted Earnings Per Share	$4.36	$9.85	$7.79
COMMON SHARES
Basic Shares Outstanding	231.9M shares	232.4M shares	237.1M shares
Diluted Shares Outstanding	233.1M shares	233.4M shares	237.8M shares

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.82B	$35.40B	$38.01B
YoY Change	-4.93%	-6.88%	17.97%
Cash & Equivalents	$7.866B	$6.497B	$9.991B
Short-Term Investments	$28.95B	$28.90B	$28.02B
Other Short-Term Assets	$5.949B	$6.464B	$4.936B
YoY Change	11.03%	30.96%	-12.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$62.85B	$62.27B	$59.74B
YoY Change	2.71%	4.24%	11.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.505B	$4.450B	$5.152B
YoY Change	6.05%	-13.63%	25.97%
Goodwill	$25.97B	$25.96B	$25.27B
YoY Change	2.67%	2.72%	3.72%
Intangibles	$10.33B	$10.45B	$10.70B
YoY Change	-1.58%	-2.39%	-0.55%
Long-Term Investments	$40.35B	$37.15B	$35.06B
YoY Change	15.59%	5.97%	5.17%
Other Assets	$2.603B	$2.196B	$2.133B
YoY Change	11.76%	2.95%	6.54%
Total Long-Term Assets	$53.69B	$50.71B	$49.43B
YoY Change	8.91%	2.61%	4.67%
TOTAL ASSETS
Total Short-Term Assets	$62.85B	$62.27B	$59.74B
Total Long-Term Assets	$53.69B	$50.71B	$49.43B
Total Assets	$116.5B	$113.0B	$109.2B
YoY Change	5.48%	3.5%	8.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.255B	$5.760B	$5.033B
YoY Change	4.55%	14.44%	-13.97%
Accrued Expenses			$895.0M
YoY Change			-2.51%
Deferred Revenue
YoY Change
Short-Term Debt	$360.0M	$225.0M	$265.0M
YoY Change		-15.09%	51.43%
Long-Term Debt Due	$2.100B	$2.900B	$0.00
YoY Change	162.83%		-100.0%
Total Short-Term Liabilities	$42.03B	$41.81B	$6.193B
YoY Change	-3.01%	575.17%	-84.24%
LONG-TERM LIABILITIES
Long-Term Debt	$24.69B	$24.56B	$24.86B
YoY Change	2.67%	-1.2%	17.45%
Other Long-Term Liabilities	$3.593B	$1.985B	$10.58B
YoY Change	82.29%	-81.23%	524.44%
Total Long-Term Liabilities	$28.28B	$26.55B	$35.44B
YoY Change	8.71%	-25.09%	55.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.03B	$41.81B	$6.193B
Total Long-Term Liabilities	$28.28B	$26.55B	$35.44B
Total Liabilities	$72.65B	$70.69B	$70.96B
YoY Change	0.99%	-0.38%	9.16%
SHAREHOLDERS EQUITY
Retained Earnings	$35.16B	$34.58B	$31.61B
YoY Change	9.51%	9.39%	9.65%
Common Stock	$2.000M	$2.000M	$2.000M
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.78B	$42.19B	$38.21B
YoY Change
Total Liabilities & Shareholders Equity	$116.5B	$113.0B	$109.2B
YoY Change	5.48%	3.5%	8.22%

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	$1.016B	$2.300B	$1.853B
YoY Change	-21.18%	24.12%	12.1%
Depreciation, Depletion And Amortization	$231.0M	$0.00	$433.0M
YoY Change	-45.77%	-100.0%	10.18%
Cash From Operating Activities	$2.678B	$426.0M	$1.950B
YoY Change	2.49%	-78.15%	-20.47%
INVESTING ACTIVITIES
Capital Expenditures	$332.0M	$323.0M	$350.0M
YoY Change	4.08%	-7.71%	-218.64%
Acquisitions
YoY Change
Other Investing Activities	-$69.00M	-$495.0M	-$322.0M
YoY Change	-81.25%	53.73%	-81.38%
Cash From Investing Activities	-$401.0M	-$818.0M	-$672.0M
YoY Change	-41.63%	21.73%	-66.8%
FINANCING ACTIVITIES
Cash Dividend Paid	$378.0M	$378.0M	$350.0M
YoY Change	8.62%	8.0%	13.27%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-915.0M	668.0M	-1.430B
YoY Change	-7.95%	-146.71%	1025.98%
NET CHANGE
Cash From Operating Activities	2.678B	426.0M	1.950B
Cash From Investing Activities	-401.0M	-818.0M	-672.0M
Cash From Financing Activities	-915.0M	668.0M	-1.430B
Net Change In Cash	1.362B	276.0M	-152.0M
YoY Change	46.14%	-281.58%	-150.5%
FREE CASH FLOW
Cash From Operating Activities	$2.678B	$426.0M	$1.950B
Capital Expenditures	$332.0M	$323.0M	$350.0M
Free Cash Flow	$2.346B	$103.0M	$1.600B
YoY Change	2.27%	-93.56%	-41.75%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	601000000	usd
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	62274000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	60029000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	867000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	890000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	849000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	876000000	usd
CY2024Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	6810000000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4450000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4359000000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	25962000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	25317000000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10447000000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2196000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1967000000	usd
CY2023Q4	us-gaap	Assets Assets	108928000000	usd
CY2024Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	15204000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1649000000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11139000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9894000000	usd
CY2024Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	165000000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41791000000	usd
CY2024Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	601000000	usd
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	62274000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	60029000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	867000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	890000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	849000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	876000000	usd
CY2024Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	6810000000	usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6107000000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4450000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4359000000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	25962000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	25317000000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10447000000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2196000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1967000000	usd
CY2024Q2	us-gaap	Assets Assets	112988000000	usd
CY2024Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	15204000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16111000000	usd
CY2024Q2	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4939000000	usd
CY2023Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5600000000	usd
CY2024Q2	us-gaap	Unearned Premiums UnearnedPremiums	1481000000	usd
CY2023Q4	us-gaap	Unearned Premiums UnearnedPremiums	1402000000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5760000000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6910000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	225000000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2900000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23246000000	usd
CY2024Q2	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	295000000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	778000000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2037000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1970000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1738000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	890000000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	849000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	876000000	usd
CY2024Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	6810000000	usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6107000000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4450000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4359000000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	25962000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	25317000000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10447000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10273000000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2196000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1967000000	usd
CY2024Q2	us-gaap	Assets Assets	112988000000	usd
CY2024Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	15204000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16111000000	usd
CY2024Q2	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4939000000	usd
CY2024Q2	us-gaap	Unearned Premiums UnearnedPremiums	1481000000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5760000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	225000000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2900000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1649000000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11139000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9894000000	usd
CY2024Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	165000000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41813000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41791000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23246000000	usd
CY2024Q2	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	295000000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	778000000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2037000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1970000000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1985000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1738000000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	70691000000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	16111000000	usd
CY2024Q2	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4939000000	usd
CY2023Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5600000000	usd
CY2024Q2	us-gaap	Unearned Premiums UnearnedPremiums	1481000000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6910000000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	225000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	225000000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2900000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1649000000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11139000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9894000000	usd
CY2024Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	165000000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41813000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41791000000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24561000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23246000000	usd
CY2024Q2	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	295000000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	778000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1970000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1738000000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	70691000000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	231902075	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231902075	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	233071088	shares
CY2024Q2	us-gaap	Liabilities Liabilities	70691000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	69523000000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	231902075	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231902075	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	233071088	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9001000000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	34575000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31749000000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1387000000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	42191000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39306000000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	106000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	99000000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42297000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39405000000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112988000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108928000000	usd
CY2024Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	35416000000	usd
CY2023Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	36589000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	71112000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	72457000000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	231902075	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231902075	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	233071088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	233071088	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9001000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8868000000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	34575000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31749000000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1387000000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	42191000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39306000000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	106000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	99000000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42297000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39405000000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112988000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108928000000	usd
CY2023Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	36589000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	72457000000	usd
CY2024Q2	elv	Operating Revenue OperatingRevenue	43223000000	usd
CY2023Q2	elv	Operating Revenue OperatingRevenue	43377000000	usd
	elv	Operating Revenue OperatingRevenue	85275000000	usd
CY2024Q2	us-gaap	Net Investment Income NetInvestmentIncome	508000000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	416000000	usd
CY2024Q2	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-85000000	usd
CY2023Q2	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-121000000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7808000000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	233071088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	233071088	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	34575000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31749000000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1387000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1313000000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	42191000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39306000000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	106000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	99000000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42297000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108928000000	usd
CY2024Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	35416000000	usd
CY2023Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	36589000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	71112000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	72457000000	usd
CY2024Q2	elv	Operating Revenue OperatingRevenue	43223000000	usd
CY2023Q2	elv	Operating Revenue OperatingRevenue	43377000000	usd
	elv	Operating Revenue OperatingRevenue	85496000000	usd
	elv	Operating Revenue OperatingRevenue	85275000000	usd
CY2024Q2	us-gaap	Net Investment Income NetInvestmentIncome	508000000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	416000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	973000000	usd
CY2024Q2	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-85000000	usd
CY2023Q2	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-121000000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024Q2	us-gaap	Revenues Revenues	43886000000	usd
	us-gaap	Revenues Revenues	86463000000	usd
	us-gaap	Revenues Revenues	85844000000	usd
CY2024Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30572000000	usd
CY2023Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	31604000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	62390000000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4820000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8645000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9618000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	456000000	usd
CY2024Q2	elv	Operating Revenue OperatingRevenue	43223000000	usd
CY2023Q2	elv	Operating Revenue OperatingRevenue	43377000000	usd
	elv	Operating Revenue OperatingRevenue	85496000000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	416000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	973000000	usd
CY2023Q2	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-121000000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
CY2024Q2	us-gaap	Revenues Revenues	43886000000	usd
CY2023Q2	us-gaap	Revenues Revenues	43672000000	usd
	us-gaap	Revenues Revenues	86463000000	usd
	us-gaap	Revenues Revenues	85844000000	usd
CY2024Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30572000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	61118000000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4820000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7808000000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5066000000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4818000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9952000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9618000000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	280000000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	261000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	512000000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	162000000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	278000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	456000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	80784000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5060000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3842000000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	240000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024Q2	us-gaap	Revenues Revenues	43886000000	usd
CY2023Q2	us-gaap	Revenues Revenues	43672000000	usd
	us-gaap	Revenues Revenues	86463000000	usd
	us-gaap	Revenues Revenues	85844000000	usd
CY2024Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	30572000000	usd
CY2023Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	31604000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	61118000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	62390000000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4820000000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4327000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8645000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7808000000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5066000000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4818000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9952000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9618000000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	280000000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	261000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	512000000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	162000000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	278000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	456000000	usd
CY2024Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	40900000000	usd
CY2023Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	41231000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	80538000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	80784000000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2986000000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2441000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5925000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5060000000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	685000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	585000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1375000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1200000000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	2301000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18000000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2300000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1853000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4546000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3842000000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.91
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	19.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	16.21
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5066000000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4818000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9952000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9618000000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	280000000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	261000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	545000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	512000000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	162000000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	221000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	278000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	456000000	usd
CY2024Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	40900000000	usd
CY2023Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	41231000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	80538000000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2986000000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2441000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5925000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5060000000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	685000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	585000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1375000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1200000000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	2301000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18000000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2300000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1853000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4546000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3842000000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	19.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	16.21
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.10
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.96
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	40900000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	80784000000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2986000000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2441000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5925000000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	685000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	585000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1375000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1200000000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	2301000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	4550000000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18000000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2300000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1853000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4546000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3842000000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.91
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	19.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	16.21
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.85
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	19.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.10
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.63
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.48
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.26
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.96
CY2024Q2	us-gaap	Profit Loss ProfitLoss	2301000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	4550000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-119000000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-82000000	usd
CY2023Q2	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-1000000	usd
	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-3000000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	15000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-5000000	usd
	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-1000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.85
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	19.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.10
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.63
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.48
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.26
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.96
CY2024Q2	us-gaap	Profit Loss ProfitLoss	2301000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	4550000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-119000000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-82000000	usd
CY2023Q2	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-1000000	usd
	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	usd
	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-3000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4000000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	15000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-4000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-8000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-5000000	usd
CY2024Q2	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	1000000	usd
CY2023Q2	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-3000000	usd
	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-1000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	326000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4166000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
	elv	Net Losses Gains On Financial Instruments NetLossesGainsOnFinancialInstruments	-234000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	19.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.10
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.63
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.48
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.26
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.96
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1856000000	usd
	us-gaap	Profit Loss ProfitLoss	4550000000	usd
	us-gaap	Profit Loss ProfitLoss	3860000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-119000000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-82000000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	308000000	usd
CY2024Q2	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	usd
	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	0	usd
	elv	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-3000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4000000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	6000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-4000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-8000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-5000000	usd
CY2024Q2	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	1000000	usd
CY2023Q2	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-3000000	usd
	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-1000000	usd
	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-1000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-116000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	326000000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4000000	usd

CY2024Q2

us-gaap

Assets Held For Sale Not Part Of Disposal Group Current

AssetsHeldForSaleNotPartOfDisposalGroupCurrent

601000000

usd

CY2023Q4

us-gaap

Assets Held For Sale Not Part Of Disposal Group Current

AssetsHeldForSaleNotPartOfDisposalGroupCurrent

0

usd

CY2024Q2

us-gaap

Assets Current

AssetsCurrent

62274000000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

60029000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

867000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

890000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

849000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

876000000

usd

CY2024Q2

us-gaap

Other Long Term Investments

OtherLongTermInvestments

6810000000

usd

CY2024Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4450000000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4359000000

usd

CY2024Q2

us-gaap

Goodwill

25962000000

usd

CY2023Q4

us-gaap

Goodwill

25317000000

usd

CY2024Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10447000000

usd

CY2024Q2

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

2196000000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1967000000

usd

CY2023Q4

us-gaap

Assets

108928000000

usd

CY2024Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15204000000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1649000000

usd

CY2024Q2

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

11139000000

usd

CY2023Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

9894000000

usd

CY2024Q2

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

165000000

usd

CY2023Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

0

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

41791000000

usd

CY2024Q2

us-gaap

Assets Held For Sale Not Part Of Disposal Group Current

AssetsHeldForSaleNotPartOfDisposalGroupCurrent

601000000

usd

CY2023Q4

us-gaap

Assets Held For Sale Not Part Of Disposal Group Current

AssetsHeldForSaleNotPartOfDisposalGroupCurrent

0

usd

CY2024Q2

us-gaap

Assets Current

AssetsCurrent

62274000000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

60029000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

867000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

890000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

849000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

876000000

usd

CY2024Q2

us-gaap

Other Long Term Investments

OtherLongTermInvestments

6810000000

usd

CY2023Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

6107000000

usd

CY2024Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4450000000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4359000000

usd

CY2024Q2

us-gaap

Goodwill

25962000000

usd

CY2023Q4

us-gaap

Goodwill

25317000000

usd

CY2024Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10447000000

usd

CY2024Q2

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

2196000000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1967000000

usd

CY2024Q2

us-gaap

Assets

112988000000

usd

CY2024Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15204000000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

16111000000

usd

CY2024Q2

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

4939000000

usd

CY2023Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

5600000000

usd

CY2024Q2

us-gaap

Unearned Premiums

UnearnedPremiums

1481000000

usd

CY2023Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1402000000

usd

CY2024Q2

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5760000000

usd

CY2023Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

6910000000

usd

CY2023Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

225000000

usd

CY2024Q2

us-gaap

Long Term Debt Current

LongTermDebtCurrent

2900000000

usd

CY2023Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

23246000000

usd

CY2024Q2

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

295000000

usd

CY2023Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

778000000

usd

CY2024Q2

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2037000000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

1970000000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1738000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

890000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

849000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

876000000

usd

CY2024Q2

us-gaap

Other Long Term Investments

OtherLongTermInvestments

6810000000

usd

CY2023Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

6107000000

usd

CY2024Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4450000000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4359000000

usd

CY2024Q2

us-gaap

Goodwill

25962000000

usd

CY2023Q4

us-gaap

Goodwill

25317000000

usd

CY2024Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10447000000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10273000000

usd

CY2024Q2

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

2196000000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1967000000

usd

CY2024Q2

us-gaap

Assets

112988000000

usd

CY2024Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15204000000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

16111000000

usd

CY2024Q2

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

4939000000

usd

CY2024Q2

us-gaap

Unearned Premiums

UnearnedPremiums

1481000000

usd

CY2024Q2

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5760000000

usd

CY2023Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

225000000

usd

CY2024Q2

us-gaap

Long Term Debt Current

LongTermDebtCurrent

2900000000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1649000000

usd

CY2024Q2

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

11139000000

usd

CY2023Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

9894000000

usd

CY2024Q2

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

165000000

usd

CY2023Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

0

usd

CY2024Q2

us-gaap

Liabilities Current

LiabilitiesCurrent

41813000000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

41791000000

usd

CY2023Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

23246000000

usd

CY2024Q2

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

295000000

usd

CY2023Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

778000000

usd

CY2024Q2

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2037000000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

1970000000

usd

CY2024Q2

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1985000000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1738000000

usd

CY2024Q2

us-gaap

Liabilities

70691000000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

16111000000

usd

CY2024Q2

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

4939000000

usd

CY2023Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

5600000000

usd

CY2024Q2

us-gaap

Unearned Premiums

UnearnedPremiums

1481000000

usd

CY2023Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

6910000000

usd

CY2024Q2

us-gaap

Short Term Borrowings

ShortTermBorrowings

225000000

usd

CY2023Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

225000000

usd

CY2024Q2

us-gaap

Long Term Debt Current

LongTermDebtCurrent

2900000000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1649000000

usd

CY2024Q2

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

11139000000

usd

CY2023Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

9894000000

usd

CY2024Q2

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

165000000

usd

CY2023Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

0

usd

CY2024Q2

us-gaap

Liabilities Current

LiabilitiesCurrent

41813000000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

41791000000

usd

CY2024Q2

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

24561000000

usd

CY2023Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

23246000000

usd

CY2024Q2

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

295000000

usd

CY2023Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

778000000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

1970000000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1738000000

usd

CY2024Q2

us-gaap

Liabilities

70691000000

usd

CY2024Q2

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2024Q2

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2023Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2024Q2

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2024Q2

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2024Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

231902075

shares

CY2024Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

231902075

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

233071088

shares

CY2024Q2

us-gaap

Liabilities

70691000000

usd

CY2023Q4

us-gaap

Liabilities

69523000000

usd

CY2024Q2

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2024Q2

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2024Q2

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2023Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2024Q2

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2024Q2

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2024Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

231902075

shares

CY2024Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

231902075

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

233071088

shares

CY2024Q2

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9001000000

usd

CY2024Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

34575000000

usd

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

31749000000

usd

CY2024Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1387000000

usd

CY2024Q2

us-gaap

Stockholders Equity

StockholdersEquity

42191000000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

39306000000

usd

CY2024Q2

us-gaap

Minority Interest

MinorityInterest

106000000

usd

CY2023Q4

us-gaap

Minority Interest

MinorityInterest

99000000

usd

CY2024Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42297000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

39405000000

usd

CY2024Q2

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

112988000000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

108928000000

usd

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

71112000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

CY2024Q2

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2023Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2024Q2

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2024Q2

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2024Q2

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2024Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

231902075

shares

CY2024Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

231902075

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

233071088

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

233071088

shares

CY2024Q2

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2023Q4

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2024Q2

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9001000000

usd

CY2023Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

8868000000

usd

CY2024Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

34575000000

usd

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

31749000000

usd

CY2024Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1387000000

usd

CY2024Q2

us-gaap

Stockholders Equity

StockholdersEquity

42191000000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

39306000000

usd

CY2024Q2

us-gaap

Minority Interest

MinorityInterest

106000000

usd

CY2023Q4

us-gaap

Minority Interest

MinorityInterest

99000000

usd

CY2024Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42297000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

39405000000

usd

CY2024Q2

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

112988000000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

108928000000

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

7808000000

usd

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

233071088

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

233071088

shares

CY2024Q2

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2023Q4

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2024Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

34575000000

usd

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

31749000000

usd

CY2024Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1387000000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1313000000

usd

CY2024Q2

us-gaap

Stockholders Equity

StockholdersEquity

42191000000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

39306000000

usd

CY2024Q2

us-gaap

Minority Interest

MinorityInterest

106000000

usd

CY2023Q4

us-gaap

Minority Interest

MinorityInterest

99000000

usd

CY2024Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42297000000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

108928000000

usd

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

71112000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

us-gaap

Revenues

86463000000

usd

us-gaap

Revenues

85844000000

usd

CY2024Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

30572000000

usd

CY2023Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

31604000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

4820000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8645000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9618000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

CY2023Q2

us-gaap

Revenues

43672000000

usd

us-gaap

Revenues

86463000000

usd

us-gaap

Revenues

85844000000

usd

CY2024Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

30572000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

CY2024Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

4820000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

7808000000

usd

CY2024Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

5066000000

usd

CY2023Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4818000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9952000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9618000000

usd

CY2024Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

280000000

usd

CY2023Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

261000000

usd

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

80784000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

3842000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

CY2023Q2

us-gaap

Revenues

43672000000

usd

us-gaap

Revenues

86463000000

usd

us-gaap

Revenues

85844000000

usd

CY2024Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

30572000000

usd

CY2023Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

31604000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

4820000000

usd

CY2023Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

4327000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8645000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

7808000000

usd

CY2024Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

5066000000

usd

CY2023Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4818000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9952000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9618000000

usd

CY2024Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

280000000

usd

CY2023Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

261000000

usd

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

40900000000

usd

CY2023Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

41231000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

80538000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

80784000000

usd

CY2024Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2986000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

1000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Net Income Loss

NetIncomeLoss

2300000000

usd

CY2023Q2

us-gaap

Net Income Loss

NetIncomeLoss

1853000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

4546000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

3842000000

usd

CY2024Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

9.91

CY2023Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

7.83

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

19.56

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

16.21

CY2024Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

5066000000

usd

CY2023Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4818000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9952000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9618000000

usd

CY2024Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

280000000

usd

CY2023Q2

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

261000000

usd

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

545000000

usd

us-gaap

Interest Expense Nonoperating

InterestExpenseNonoperating

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

40900000000

usd

CY2023Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

41231000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

80538000000

usd

CY2024Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2986000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

1000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

4000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Net Income Loss

NetIncomeLoss

2300000000

usd

CY2023Q2

us-gaap

Net Income Loss

NetIncomeLoss

1853000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

4546000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

3842000000

usd

CY2024Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

9.91

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

19.56

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

16.21

CY2024Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

9.85

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

16.10

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

2.96

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

40900000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

80784000000

usd

CY2024Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2986000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

4000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Net Income Loss

NetIncomeLoss

2300000000

usd

CY2023Q2

us-gaap

Net Income Loss

NetIncomeLoss

1853000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

4546000000

usd

us-gaap

Net Income Loss

NetIncomeLoss

3842000000

usd

CY2024Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

9.91

CY2023Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

7.83

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

19.56

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

16.21

CY2024Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

9.85

CY2023Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

7.79

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

19.44

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

16.10

CY2024Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.63

CY2023Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.48

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.26

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

2.96

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-26000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-119000000

usd

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-82000000

usd

CY2023Q2

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-3000000

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

15000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-5000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2000000

usd

CY2024Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

9.85

CY2023Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

7.79

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

19.44

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

16.10

CY2024Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.63

CY2023Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.48

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.26

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

2.96

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-26000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-119000000

usd

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-82000000

usd

CY2023Q2

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-3000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

4000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

4000000

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

15000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-4000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-8000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-5000000

usd

CY2024Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

1000000

usd

CY2023Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-3000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4166000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

7.79

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

19.44

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

16.10

CY2024Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.63

CY2023Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.48

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.26

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

2.96

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-26000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-119000000

usd

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-82000000

usd

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

308000000

usd

CY2024Q2

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

0

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-3000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

4000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

4000000

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

6000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-4000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-8000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-5000000

usd

CY2024Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

1000000

usd

CY2023Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-3000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

1000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

4000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

CY2024Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

2278000000

usd

CY2023Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1737000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4472000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4166000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-26000000

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-73000000

usd

elv

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-3000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

4000000

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

6000000

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

15000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-4000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-8000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-5000000

usd

CY2024Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

1000000

usd

CY2023Q2

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-3000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

us-gaap

Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax

OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax

-1000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-5000000

usd

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

1000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

4000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2024Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

2278000000

usd

CY2023Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1737000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4472000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4166000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-26000000

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-73000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

666000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

895000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

1000000

usd

CY2023Q2

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

3000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

18000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

CY2024Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

2278000000

usd

CY2023Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1737000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

4472000000

usd

us-gaap

Profit Loss

ProfitLoss

4550000000

usd

us-gaap

Profit Loss

ProfitLoss

3860000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-26000000

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-73000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

666000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

895000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-34000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-393000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

154000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

139000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1341000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

299000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

47000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

42000000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

789000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-1366000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

583000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

80000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-26000000

usd

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-73000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

666000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

895000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-34000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-393000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

154000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

139000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1341000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

299000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

47000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

42000000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

789000000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

529000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-1366000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

583000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

80000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

3346000000

usd

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

300000000

usd

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

160000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

174000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

391000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-46000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-1000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

2425000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8419000000

usd

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

10035000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1036000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

10656000000

usd

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

321000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

399000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

0

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1124000000

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1651000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

320000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-145000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-479000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-500000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1029000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1268000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

757000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

701000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

666000000

usd

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

895000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-34000000

usd

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-393000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

154000000

usd

us-gaap

Share Based Compensation

ShareBasedCompensation

139000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1341000000

usd

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

299000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

47000000

usd

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

42000000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

789000000

usd

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

529000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-1366000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

583000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

80000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

3346000000

usd

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

300000000

usd

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

160000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

174000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

391000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-46000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-1000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

2425000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8419000000

usd

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

10035000000

usd

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

17648000000

usd

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

7584000000

usd

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

5339000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1036000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

10656000000

usd

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

321000000

usd

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-145000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

399000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

0

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1124000000

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1651000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

602000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

651000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

46000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3128000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3856000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2580000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2574000000

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1908000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

320000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-145000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-479000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1029000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1268000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

757000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

701000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

157000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

81000000

usd

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

3346000000

usd

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

300000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

174000000

usd

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

391000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-46000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-1000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

2425000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8419000000

usd

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

10035000000

usd

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

7584000000

usd

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

5339000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1036000000

usd

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

10656000000

usd

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

321000000

usd

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-145000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

399000000

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1651000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

602000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

651000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

46000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3128000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3856000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2580000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2574000000

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1908000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

320000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-145000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-479000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-500000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1029000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1268000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

757000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

701000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

157000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

100000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

99000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

8000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

5000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

700000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1961000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-5000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

2000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-8000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

2604000000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

6526000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

7387000000

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

21000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

0

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

6497000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9991000000

usd

CY2024Q1

us-gaap

Profit Loss

ProfitLoss

2249000000

usd

CY2024Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-52000000

usd

CY2024Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

569000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

602000000

usd

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

651000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

65000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

46000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3128000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-3856000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2580000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2574000000

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1908000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

320000000

usd

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-145000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-479000000

usd

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-500000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1029000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1268000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

757000000

usd

us-gaap

Payments Of Dividends

PaymentsOfDividends

701000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

157000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

81000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

100000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

99000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

8000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

5000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

700000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1961000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-5000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

2000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-8000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

2604000000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

6526000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

7387000000

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

21000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

0

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

6497000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9991000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

39405000000

usd

CY2024Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

569000000

usd

CY2024Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

382000000

usd

CY2024Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

59000000

usd

CY2024Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

40710000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2024Q2

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

3000000

usd

CY2024Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

466000000

usd

CY2024Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

381000000

usd

CY2024Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

152000000

usd

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36330000000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

2004000000

usd

CY2023Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

442000000

usd

CY2023Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

626000000

usd

CY2023Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

354000000

usd

CY2023Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

6000000

usd

CY2023Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

342000000

usd

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

81000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

100000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

99000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

8000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

5000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

700000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1961000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-5000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

2000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-8000000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

6526000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

7387000000

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

21000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

0

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

6497000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9991000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

39405000000

usd

CY2024Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-52000000

usd

CY2024Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

569000000

usd

CY2024Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

382000000

usd

CY2024Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

59000000

usd

CY2024Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

40710000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2024Q2

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

3000000

usd

CY2024Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

466000000

usd

CY2024Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

381000000

usd

CY2024Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

152000000

usd

CY2024Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42297000000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

2004000000

usd

CY2023Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

442000000

usd

CY2023Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

626000000

usd

CY2023Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

354000000

usd

CY2023Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

6000000

usd

CY2023Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

342000000

usd

CY2023Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

37460000000

usd

CY2023Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

652000000

usd

CY2023Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

116000000

usd

CY2023Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

38312000000

usd

us-gaap

Nature Of Operations

NatureOfOperations

Organization<div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</div><div style="margin-bottom:9pt;text-indent:18pt">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving nearly 46 million medical members through our affiliated health plans as of June 30, 2024. As a lifetime, trusted health partner, we offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </div><div style="margin-bottom:9pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health and Carelon Behavioral Health. </div><div style="margin-bottom:6pt;text-indent:18pt">We have organized our brand portfolio into the following core go-to-market brands:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </div><div style="margin-bottom:12pt;text-indent:18pt">We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15, “Segment Information” included in this Quarterly Report on Form 10-Q.</div>

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

100000000

usd

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

99000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

8000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

700000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1961000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-5000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

2000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-8000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

2604000000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

6526000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

7387000000

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

21000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

0

usd

CY2024Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

6497000000

usd

CY2023Q2

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9991000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

39405000000

usd

CY2024Q1

us-gaap

Profit Loss

ProfitLoss

2249000000

usd

CY2024Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-52000000

usd

CY2024Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

569000000

usd

CY2024Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

382000000

usd

CY2024Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

59000000

usd

CY2024Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

40710000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2024Q2

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

3000000

usd

CY2024Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

466000000

usd

CY2024Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

381000000

usd

CY2024Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

152000000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

2004000000

usd

CY2023Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

442000000

usd

CY2023Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

626000000

usd

CY2023Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

354000000

usd

CY2023Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

6000000

usd

CY2023Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

342000000

usd

CY2023Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

37460000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

CY2023Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

652000000

usd

CY2023Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

352000000

usd

CY2023Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

116000000

usd

CY2023Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

38312000000

usd

us-gaap

Nature Of Operations

NatureOfOperations

Organization<div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</div><div style="margin-bottom:9pt;text-indent:18pt">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving nearly 46 million medical members through our affiliated health plans as of June 30, 2024. As a lifetime, trusted health partner, we offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </div><div style="margin-bottom:9pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health and Carelon Behavioral Health. </div><div style="margin-bottom:6pt;text-indent:18pt">We have organized our brand portfolio into the following core go-to-market brands:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </div><div style="margin-bottom:12pt;text-indent:18pt">We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15, “Segment Information” included in this Quarterly Report on Form 10-Q.</div>

CY2024Q2

elv

Number Of Medical Members Served

NumberOfMedicalMembersServed

46000000

individual

CY2024Q2

elv

Number Of Counties In State Of Kansas Company Does Not Serve

NumberOfCountiesInStateOfKansasCompanyDoesNotServe

30

county

CY2024Q2

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

state

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2024Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

382000000

usd

CY2024Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

59000000

usd

CY2024Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

40710000000

usd

CY2024Q2

us-gaap

Profit Loss

ProfitLoss

2301000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2024Q2

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

3000000

usd

CY2024Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

466000000

usd

CY2024Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

152000000

usd

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36330000000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

2004000000

usd

CY2023Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

442000000

usd

CY2023Q1

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

626000000

usd

CY2023Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

354000000

usd

CY2023Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

6000000

usd

CY2023Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

342000000

usd

CY2023Q2

us-gaap

Profit Loss

ProfitLoss

1856000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

CY2023Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

652000000

usd

CY2023Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

352000000

usd

CY2023Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

116000000

usd

CY2023Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

38312000000

usd

us-gaap

Nature Of Operations

NatureOfOperations

Organization<div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</div><div style="margin-bottom:9pt;text-indent:18pt">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving nearly 46 million medical members through our affiliated health plans as of June 30, 2024. As a lifetime, trusted health partner, we offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </div><div style="margin-bottom:9pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health and Carelon Behavioral Health. </div><div style="margin-bottom:6pt;text-indent:18pt">We have organized our brand portfolio into the following core go-to-market brands:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </div><div style="margin-bottom:12pt;text-indent:18pt">We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15, “Segment Information” included in this Quarterly Report on Form 10-Q.</div>

CY2024Q2

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

400000000

usd

CY2024Q2

elv

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2023Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

37460000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

CY2023Q2

elv

Stock Repurchased And Retired During Period Value Including Excise Tax

StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax

652000000

usd

CY2023Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

352000000

usd

CY2023Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

116000000

usd

CY2023Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

38312000000

usd

us-gaap

Nature Of Operations

NatureOfOperations

Organization<div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</div><div style="margin-bottom:9pt;text-indent:18pt">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving nearly 46 million medical members through our affiliated health plans as of June 30, 2024. As a lifetime, trusted health partner, we offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </div><div style="margin-bottom:9pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health and Carelon Behavioral Health. </div><div style="margin-bottom:6pt;text-indent:18pt">We have organized our brand portfolio into the following core go-to-market brands:</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt">•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </div><div style="margin-bottom:12pt;text-indent:18pt">We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15, “Segment Information” included in this Quarterly Report on Form 10-Q.</div>

CY2024Q2

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

state

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2024Q2

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

400000000

usd

CY2024Q2

elv

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2024Q2

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

177000000

usd

CY2023Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

212000000

usd

CY2024Q2

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2023Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2024Q2

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

1046000000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

941000000

usd

CY2023Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

294000000

usd

CY2024Q2

elv

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2024Q2

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

177000000

usd

CY2023Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

212000000

usd

CY2024Q2

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2023Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2024Q2

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

1046000000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

941000000

usd

CY2024Q2

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

400000000

usd

CY2023Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

294000000

usd

CY2024Q2

elv

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2024Q2

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

177000000

usd

CY2023Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

212000000

usd

CY2024Q2

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2023Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2024Q2

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

1046000000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

941000000

usd

CY2024Q2

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

177000000

usd

CY2023Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

212000000

usd

CY2024Q2

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2023Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

87000000

usd

CY2024Q2

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

1046000000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

941000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

313000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1261000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

31336000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

496000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1338000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

2052000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

7964000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

138000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

5077000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

10919000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1123000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

1032000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

2699000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

55000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

6659000000

security

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

30701000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

313000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1261000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

31336000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1338000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

2052000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

7964000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

138000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

5077000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

10919000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1123000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

1032000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

2699000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

55000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

6659000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

14842000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1283000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

313000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1261000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

31336000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

496000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1338000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

2052000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

7964000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

138000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

5077000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

10919000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1123000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

1032000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

2699000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

55000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

6659000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

14842000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1283000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

30701000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

313000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1261000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

31336000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

496000000

usd

CY2023Q4

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

1338000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

2052000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

7964000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

138000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

5077000000

security

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

10919000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1123000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions

1032000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

2699000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

55000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

6659000000

security

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

14842000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1283000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

5510000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

14842000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

1283000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

5510000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

5376000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost

11319000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

11055000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost

7559000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue

7369000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

6116000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue

5752000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

30701000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

3014000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

8414000000

usd

CY2023Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

9675000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

15085000000

usd

CY2024Q2

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

594000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

229000000

usd

CY2024Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-87000000

usd

CY2023Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-128000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-253000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-219000000

usd

CY2024Q2

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

316000000

usd

CY2023Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

301000000

usd

CY2024Q2

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2700000000

usd

CY2023Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2380000000

usd

CY2023Q4

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

4000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

5510000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

5376000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost

11319000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

11055000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue

7369000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

6116000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue

5752000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

30701000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

3014000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

8414000000

usd

CY2023Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

9675000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

15085000000

usd

CY2024Q2

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

594000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

229000000

usd

CY2024Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-87000000

usd

CY2023Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-128000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-253000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-219000000

usd

CY2024Q2

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

316000000

usd

CY2023Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

301000000

usd

CY2024Q2

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2700000000

usd

CY2023Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2380000000

usd

CY2023Q4

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

197000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

5510000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

5376000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost

11319000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

11055000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost

7559000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue

5752000000

usd

CY2024Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

30701000000

usd

CY2024Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

3014000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

8414000000

usd

CY2023Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

9675000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

15085000000

usd

CY2024Q2

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

594000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

229000000

usd

CY2024Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-87000000

usd

CY2023Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-128000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-253000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-219000000

usd

CY2024Q2

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

316000000

usd

CY2023Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

301000000

usd

CY2024Q2

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2700000000

usd

CY2023Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2380000000

usd

CY2023Q4

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

2000000

usd

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

5376000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost

11319000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

11055000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities After Ten Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost

7559000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

6116000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

3014000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

8414000000

usd

CY2023Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

9675000000

usd

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

15085000000

usd

CY2024Q2

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

594000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

229000000

usd

CY2024Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-87000000

usd

CY2023Q2

elv

Investment Gains Losses

InvestmentGainsLosses

-128000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-253000000

usd

elv

Investment Gains Losses

InvestmentGainsLosses

-219000000

usd

CY2024Q2

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

316000000

usd

CY2023Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

301000000

usd

CY2024Q2

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2700000000

usd

CY2023Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2380000000

usd

CY2023Q4

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2024Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

2000000

usd

CY2023Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

us-gaap

Derivative Loss On Derivative

DerivativeLossOnDerivative

15000000

usd

CY2024Q2

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1508000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2701000000

usd

CY2024Q2

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

34577000000

usd

CY2024Q2

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2024Q2

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

55000000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2210000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2023Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2382000000

usd

CY2024Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

2000000

usd

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

us-gaap

Derivative Loss On Derivative

DerivativeLossOnDerivative

15000000

usd

CY2024Q2

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1508000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2701000000

usd

CY2024Q2

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

34577000000

usd

CY2024Q2

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2024Q2

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

55000000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2210000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2023Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2382000000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

35432000000

usd

CY2023Q4

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

40000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

CY2024Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.229

CY2023Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.240

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.237

CY2024Q2

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

369000000

usd

CY2023Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

543000000

usd

CY2024Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

2000000

usd

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

CY2023Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

us-gaap

Derivative Loss On Derivative

DerivativeLossOnDerivative

15000000

usd

CY2024Q2

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1508000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2701000000

usd

CY2024Q2

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

34577000000

usd

CY2024Q2

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2024Q2

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

55000000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2210000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2023Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2382000000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

35432000000

usd

CY2023Q4

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

40000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

CY2024Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.229

CY2023Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.240

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.232

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.237

CY2024Q2

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

369000000

usd

CY2023Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

543000000

usd

CY2023Q2

us-gaap

Derivative Gain On Derivative

DerivativeGainOnDerivative

7000000

usd

us-gaap

Derivative Loss On Derivative

DerivativeLossOnDerivative

15000000

usd

CY2024Q2

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1508000000

usd

CY2024Q2

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

29749000000

usd

CY2024Q2

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2701000000

usd

CY2024Q2

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

34577000000

usd

CY2024Q2

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2024Q2

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

55000000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2210000000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

30490000000

usd

CY2023Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2382000000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

35432000000

usd

CY2023Q4

elv

Percentage Of Total Assets Presented At Fair Value

PercentageOfTotalAssetsPresentedAtFairValue

1

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

40000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

CY2024Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.229

CY2023Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.240

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.237

CY2024Q2

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

369000000

usd

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:9pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2024 and 2023 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,865 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,348 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,858 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,290 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods redundancies</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,473)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,078 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,178 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods medical claims</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,409 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,881 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,626 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,894 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,067 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15865000000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

35432000000

usd

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

40000000

usd

CY2024Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

685000000

usd

CY2023Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

585000000

usd

CY2024Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.229

CY2023Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.240

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1375000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1200000000

usd

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.232

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.237

CY2024Q2

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

369000000

usd

CY2023Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

543000000

usd

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:9pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2024 and 2023 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,865 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,348 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,858 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,290 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods redundancies</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,473)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,078 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,178 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods medical claims</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,409 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,881 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,626 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,894 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,067 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2022Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15348000000

usd

CY2023Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

7000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

CY2023Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15858000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

60551000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

61290000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1473000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1112000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48297000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48217000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11584000000

usd

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:9pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2024 and 2023 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,865 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,348 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,858 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,290 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods redundancies</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,473)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,078 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,178 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods medical claims</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,409 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,881 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,626 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,894 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,067 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15865000000

usd

CY2022Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15348000000

usd

CY2023Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

7000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

CY2023Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15858000000

usd

CY2022Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15342000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

60551000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

61290000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1473000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1112000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48297000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48217000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11584000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11409000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59881000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59626000000

usd

CY2024Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15055000000

usd

CY2023Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15894000000

usd

CY2024Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

12000000

usd

CY2023Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

8000000

usd

CY2024Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15067000000

usd

CY2023Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15902000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2040000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2212000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Ceded Medical Claims Payable

LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable

12000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Liabilities Held For Sale

LiabilityForClaimsAndClaimsAdjustmentExpenseLiabilitiesHeldForSale

111000000

usd

CY2022Q3

us-gaap

Loss Contingency Accrual Payments

LossContingencyAccrualPayments

506000000

usd

CY2022Q3

elv

Number Of Notices Of Appeal

NumberOfNoticesOfAppeal

4

appeal

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:9pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2024 and 2023 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,865 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,348 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,858 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,290 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods redundancies</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,473)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,078 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,178 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Current period medical claims</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Prior periods medical claims</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,409 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,881 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,626 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,894 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of period</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,067 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2022Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15348000000

usd

CY2023Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

7000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

CY2023Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15858000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

60551000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

61290000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1473000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48297000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48217000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11584000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11409000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59881000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59626000000

usd

CY2024Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15055000000

usd

CY2023Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15894000000

usd

CY2024Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

12000000

usd

CY2023Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15902000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2040000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2212000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

15055000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Ceded Medical Claims Payable

LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable

12000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Other Insurance Lines

LiabilityForClaimsAndClaimsAdjustmentExpenseOtherInsuranceLines

248000000

usd

CY2023Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

7000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

60551000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

61290000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1473000000

usd

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

-1112000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48297000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

48217000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11584000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11409000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59881000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59626000000

usd

CY2024Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15055000000

usd

CY2023Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15894000000

usd

CY2024Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

12000000

usd

CY2023Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

8000000

usd

CY2024Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15067000000

usd

CY2023Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15902000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2040000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2212000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

15055000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Other Insurance Lines

LiabilityForClaimsAndClaimsAdjustmentExpenseOtherInsuranceLines

248000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Liabilities Held For Sale

LiabilityForClaimsAndClaimsAdjustmentExpenseLiabilitiesHeldForSale

111000000

usd

CY2022Q3

us-gaap

Loss Contingency Accrual Payments

LossContingencyAccrualPayments

506000000

usd

CY2022Q3

elv

Number Of Notices Of Appeal

NumberOfNoticesOfAppeal

4

appeal

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11409000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59881000000

usd

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

59626000000

usd

CY2024Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15055000000

usd

CY2023Q2

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15894000000

usd

CY2024Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

12000000

usd

CY2023Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

8000000

usd

CY2024Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15067000000

usd

CY2023Q2

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15902000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

59078000000

usd

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

60178000000

usd

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

2040000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

61118000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

62390000000

usd

CY2024Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

15055000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Ceded Medical Claims Payable

LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable

12000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Liabilities Held For Sale

LiabilityForClaimsAndClaimsAdjustmentExpenseLiabilitiesHeldForSale

111000000

usd

CY2024Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15204000000

usd

CY2022Q3

us-gaap

Loss Contingency Accrual Payments

LossContingencyAccrualPayments

506000000

usd

CY2022Q3

elv

Number Of Notices Of Appeal

NumberOfNoticesOfAppeal

4

appeal

CY2024Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

379000000

usd

CY2024Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

378000000

usd

CY2023Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

350000000

usd

CY2023Q1

elv

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

usd

CY2024Q2

elv

Liability For Claims And Claims Adjustment Expense Liabilities Held For Sale

LiabilityForClaimsAndClaimsAdjustmentExpenseLiabilitiesHeldForSale

111000000

usd

CY2024Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15204000000

usd

CY2022Q3

us-gaap

Loss Contingency Accrual Payments

LossContingencyAccrualPayments

506000000

usd

CY2022Q3

elv

Number Of Notices Of Appeal

NumberOfNoticesOfAppeal

4

appeal

CY2024Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

379000000

usd

CY2023Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

351000000

usd

CY2023Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.48

CY2023Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

350000000

usd

CY2023Q1

elv

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

usd

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2000000.0

shares

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2700000

shares

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

506.55

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

466.62

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1029000000

usd

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1268000000

usd

CY2024Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3171000000

usd

CY2023Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5608000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

327.14

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

500000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

499.31

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

400000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

287.38

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

453.92

CY2024Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

379000000

usd

CY2023Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

351000000

usd

CY2023Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.48

CY2023Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

350000000

usd

CY2023Q1

elv

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

usd

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2000000.0

shares

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2700000

shares

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

506.55

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

466.62

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1029000000

usd

CY2024Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3171000000

usd

CY2023Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5608000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

327.14

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

500000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

499.31

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

400000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

287.38

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

453.92

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

359.56

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y2M4D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

554000000

usd

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

298.49

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y11M12D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

492000000

usd

CY2024Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

379000000

usd

CY2024Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.63

CY2024Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

378000000

usd

CY2023Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.48

CY2023Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

351000000

usd

CY2023Q1

elv

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

usd

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2000000.0

shares

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2700000

shares

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

506.55

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

466.62

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1029000000

usd

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1268000000

usd

CY2024Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3171000000

usd

CY2023Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5608000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

500000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

499.31

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

400000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

287.38

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

453.92

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

359.56

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y2M4D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

554000000

usd

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

298.49

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y11M12D

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2000000.0

shares

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2700000

shares

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

506.55

us-gaap

Treasury Stock Acquired Average Cost Per Share

TreasuryStockAcquiredAverageCostPerShare

466.62

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1029000000

usd

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1268000000

usd

CY2024Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3171000000

usd

CY2023Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5608000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

327.14

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

500000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

499.31

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

400000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

287.38

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

453.92

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

359.56

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y2M4D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

554000000

usd

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

298.49

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y11M12D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

492000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

423.94

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

354.27

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

359.56

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y2M4D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

554000000

usd

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2000000.0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

298.49

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y11M12D

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

492000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

423.94

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

469.96

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

476.95

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0428

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0395

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2800

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00327

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00316

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

134.57

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

127.13

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

469.60

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

7000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

32000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

22000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-72000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

492000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

423.94

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

0

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

476.95

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0428

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0395

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2800

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2900

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00327

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00316

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

134.57

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

127.13

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

469.60

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

7000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

22000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-72000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

423.94

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

600000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

0

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

469.96

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

476.95

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0428

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0395

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2800

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00327

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00316

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

134.57

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

127.13

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

469.60

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

7000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

32000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

22000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-72000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

469.96

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1100000

shares

CY2024Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

476.95

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0428

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0395

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2800

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00327

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00316

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

134.57

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

127.13

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

500.66

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

469.60

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

7000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

32000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

22000000

usd

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-72000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-22000000

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-116000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

326000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-74000000

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2024Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232200000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

236600000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232400000

shares

CY2024Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

CY2023Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1400000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1700000

shares

CY2024Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233400000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

237800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

238700000

shares

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2024Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43223000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2024Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

CY2023Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85496000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85275000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2024Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2023Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

2000000

usd

CY2024Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232200000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

236600000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232400000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

237000000.0

shares

CY2024Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

CY2023Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1400000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1700000

shares

CY2024Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233400000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

238700000

shares

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2024Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43223000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2024Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

CY2023Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43377000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

CY2023Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

71112000000

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85496000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85275000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2024Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232200000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

236600000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232400000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

237000000.0

shares

CY2024Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

CY2023Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1400000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1700000

shares

CY2024Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233400000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

237800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

238700000

shares

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2024Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43223000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2024Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

CY2023Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43377000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

CY2023Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

72457000000

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85275000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2024Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232200000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

236600000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

232400000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

237000000.0

shares

CY2024Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

CY2023Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1200000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1400000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

1700000

shares

CY2024Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233400000

shares

CY2023Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

237800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

233800000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

238700000

shares

CY2024Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

35416000000

usd

CY2024Q2

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

43223000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2024Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2023Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

36589000000

usd

CY2023Q2

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

71112000000

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85496000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

elv

Premiums Earned And Other Operating Revenue

PremiumsEarnedAndOtherOperatingRevenue

85275000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

0

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

CY2023Q2

us-gaap

Revenues

43672000000

usd

us-gaap

Revenues

86463000000

usd

us-gaap

Revenues

85844000000

usd

CY2024Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2986000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Interest Expense

InterestExpense

280000000

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

CY2023Q2

us-gaap

Revenues

43672000000

usd

us-gaap

Revenues

85844000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Interest Expense

InterestExpense

280000000

usd

us-gaap

Interest Expense

InterestExpense

545000000

usd

us-gaap

Interest Expense

InterestExpense

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

CY2024Q2

ecd

Non Rule10b51 Arr Adopted Flag

NonRule10b51ArrAdoptedFlag

false

CY2024Q2

ecd

Rule10b51 Arr Trmntd Flag

Rule10b51ArrTrmntdFlag

false

CY2024Q2

ecd

Non Rule10b51 Arr Trmntd Flag

NonRule10b51ArrTrmntdFlag

false

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

CY2023Q2

elv

Operating Revenue

OperatingRevenue

43377000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

us-gaap

Revenues

86463000000

usd

us-gaap

Revenues

85844000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Interest Expense

InterestExpense

280000000

usd

CY2023Q2

us-gaap

Interest Expense

InterestExpense

261000000

usd

us-gaap

Interest Expense

InterestExpense

545000000

usd

us-gaap

Interest Expense

InterestExpense

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

CY2024Q2

elv

Operating Revenue

OperatingRevenue

43223000000

usd

elv

Operating Revenue

OperatingRevenue

85496000000

usd

elv

Operating Revenue

OperatingRevenue

85275000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

CY2023Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-121000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Revenues

43886000000

usd

us-gaap

Revenues

85844000000

usd

CY2024Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2986000000

usd

CY2023Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2441000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5925000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5060000000

usd

CY2024Q2

us-gaap

Net Investment Income

NetInvestmentIncome

508000000

usd

CY2023Q2

us-gaap

Net Investment Income

NetInvestmentIncome

416000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

973000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

803000000

usd

CY2024Q2

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-85000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-246000000

usd

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-234000000

usd

CY2024Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

CY2023Q2

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

240000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

0

usd

CY2024Q2

us-gaap

Interest Expense

InterestExpense

280000000

usd

CY2023Q2

us-gaap

Interest Expense

InterestExpense

261000000

usd

us-gaap

Interest Expense

InterestExpense

545000000

usd

us-gaap

Interest Expense

InterestExpense

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

CY2023Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

221000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

CY2024Q2

ecd

Non Rule10b51 Arr Adopted Flag

NonRule10b51ArrAdoptedFlag

false

CY2024Q2

ecd

Rule10b51 Arr Trmntd Flag

Rule10b51ArrTrmntdFlag

false

CY2024Q2

ecd

Non Rule10b51 Arr Trmntd Flag

NonRule10b51ArrTrmntdFlag

false

CY2023Q2

us-gaap

Interest Expense

InterestExpense

261000000

usd

us-gaap

Interest Expense

InterestExpense

545000000

usd

us-gaap

Interest Expense

InterestExpense

512000000

usd

CY2024Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

162000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

CY2024Q2

ecd

Non Rule10b51 Arr Adopted Flag

NonRule10b51ArrAdoptedFlag

false

CY2024Q2

ecd

Rule10b51 Arr Trmntd Flag

Rule10b51ArrTrmntdFlag

false

CY2024Q2

ecd

Non Rule10b51 Arr Trmntd Flag

NonRule10b51ArrTrmntdFlag

false

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

278000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

456000000

usd

CY2024Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2765000000

usd

CY2023Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

2628000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5781000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

5459000000

usd

CY2024Q2

ecd

Non Rule10b51 Arr Adopted Flag

NonRule10b51ArrAdoptedFlag

false

CY2024Q2

ecd

Rule10b51 Arr Trmntd Flag

Rule10b51ArrTrmntdFlag

false

CY2024Q2

ecd

Non Rule10b51 Arr Trmntd Flag

NonRule10b51ArrTrmntdFlag

false

Name	View Source	Status
0001156039-24-000104-index-headers.html	Edgar Link	pending
0001156039-24-000104-index.html	Edgar Link	pending
0001156039-24-000104.txt	Edgar Link	pending
0001156039-24-000104-xbrl.zip	Edgar Link	pending
elv-20240630.htm	Edgar Link	pending
elv-20240630.xsd	Edgar Link	pending
elv-20240630_g1.jpg	Edgar Link	pending
exhibit311-20240630q22024.htm	Edgar Link	pending
exhibit312-20240630q22024.htm	Edgar Link	pending
exhibit321-20240630q22024.htm	Edgar Link	pending
exhibit322-20240630q22024.htm	Edgar Link	pending
elv-20240630_cal.xml	Edgar Link	unprocessable
elv-20240630_def.xml	Edgar Link	unprocessable
elv-20240630_pre.xml	Edgar Link	unprocessable
elv-20240630_lab.xml	Edgar Link	unprocessable
elv-20240630_htm.xml	Edgar Link	completed
0001156039-24-000104-index-headers.html	Edgar Link	pending
0001156039-24-000104-index.html	Edgar Link	pending
0001156039-24-000104.txt	Edgar Link	pending
0001156039-24-000104-xbrl.zip	Edgar Link	pending
elv-20240630.htm	Edgar Link	pending
elv-20240630.xsd	Edgar Link	pending
elv-20240630_g1.jpg	Edgar Link	pending
exhibit311-20240630q22024.htm	Edgar Link	pending
exhibit312-20240630q22024.htm	Edgar Link	pending
exhibit321-20240630q22024.htm	Edgar Link	pending
exhibit322-20240630q22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
elv-20240630_cal.xml	Edgar Link	unprocessable
elv-20240630_def.xml	Edgar Link	unprocessable
elv-20240630_lab.xml	Edgar Link	unprocessable
elv-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elv-20240630_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2024 Q3 Form 10-Q Financial Statement

#000115603924000104 Filed on July 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2024 Q3 Form 10-Q Financial Statement

#000115603924000104 Filed on July 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv